Abstract: The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof which modulate the activity of calcium release activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating managing and/or lessening the severity of diseases disorders syndromes or conditions associated with the modulation of calcium release activated calcium (CRAC) channel.
| # | Name | Date |
|---|---|---|
| 1 | 2127-MUMNP-2014-FORM 1(19-11-2014).pdf | 2014-11-19 |
| 2 | 2127-MUMNP-2014-CORRESPONDENCE(19-11-2014).pdf | 2014-11-19 |
| 3 | Other Document [24-08-2016(online)].pdf | 2016-08-24 |
| 4 | Form 13 [24-08-2016(online)].pdf | 2016-08-24 |
| 5 | Other Patent Document [09-05-2017(online)].pdf | 2017-05-09 |
| 6 | 2127-MUMNP-2014-FORM 3 [11-04-2018(online)].pdf | 2018-04-11 |
| 7 | PCT IB 304.pdf | 2018-08-11 |
| 8 | GPA of Lupin Limited.pdf | 2018-08-11 |
| 9 | FORM 5.pdf | 2018-08-11 |
| 10 | FORM 3.pdf | 2018-08-11 |
| 11 | FORM 2 & Complete Specification.pdf | 2018-08-11 |
| 12 | ABSTRACT1.jpg | 2018-08-11 |
| 13 | 2127-MUMNP-2014.pdf | 2018-08-11 |
| 14 | 2127-MUMNP-2014-Form 3-130115.pdf | 2018-08-11 |
| 15 | 2127-MUMNP-2014-FER.pdf | 2018-08-11 |
| 16 | 2127-MUMNP-2014-Correspondence-130115.pdf | 2018-08-11 |
| 17 | 2127-MUMNP-2014-CORRESPONDENCE-(09-02-15).pdf | 2018-08-11 |
| 18 | 2127-MUMNP-2014-ANNEXURE TO FORM 3-(09-02-15).pdf | 2018-08-11 |
| 19 | 2127-MUMNP-2014-FORM 3 [10-11-2018(online)].pdf | 2018-11-10 |
| 20 | 2127-MUMNP-2014-AbandonedLetter.pdf | 2024-02-09 |
| 1 | SearchStrategy2127_31-05-2018.pdf |